MARKER THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
MARKER THERAPEUTICS, INC. (MRKR) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $358.91 thousand for the 12-month period ending 2007-12-31, per its 10-K filed 2012-04-16.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2012-04-16
- MARKER THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2007 was $358.91K, a 74.58% increase from fiscal 2006.
- MARKER THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2006 was $205.58K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|
| 2007-12-31 | $358.91K 10-K · filed 2012-04-16 |
| 2006-12-31 | $205.58K 10-K · filed 2012-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |